Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1

Interventions

Cyclophosphamide 414Cytarabine 336fludarabine phosphate 231Rituximab 206Methotrexate 198fludarabine 196venetoclax 174Azacitidine 174Busulfan 169Filgrastim 145Whole-Body Irradiation 143Mycophenolic Acid 143Peripheral Blood Stem Cell Transplantation 141Tacrolimus 138Etoposide 130Vincristine 112Melphalan 110Dexamethasone 109Cyclosporine 102Granulocyte Colony-Stimulating Factor 100Imatinib Mesylate 94Antilymphocyte Serum 91Daunorubicin 90Radiotherapy 84Decitabine 83Dasatinib 76Lenalidomide 75Doxorubicin 70Prednisone 69Idarubicin 68

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × BEBT-908 × Other hematologic neoplasm × Clear all
NCT07301138 2025-12-24

BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients

Ruijin Hospital

Phase 2 Not yet recruiting
23 enrolled
LymphoidOther hematologic neoplasm

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡